S100A2 and familial pancreatic carcinoma: Fourth, although previous studies reported a similar efficacy of S100A2 in patients who received adjuvant chemotherapy, it has recently been shown that increased S100A2 expression is associated with squamous and basal-type pancreatic cancers with poor prognosis.